<DOC>
	<DOCNO>NCT02665039</DOCNO>
	<brief_summary>This study aim compare efficacy , safety quality life vinflunine/gemcitabine carboplatin/gemcitabine patient metastatic urothelial cancer impair renal function .</brief_summary>
	<brief_title>A Trial With Vinflunine Patients With Metastatic Bladder Cancer Impaired Renal Function</brief_title>
	<detailed_description>Rational The standard first line treatment patient metastatic urothelial carcinoma unfit cisplatin due renal impairment carboplatin contain chemotherapy , median overall survival approximately 8-10 month . New , effective regimen term tumor control quality life urgently need . Vinflunine proven efficacy urothelial carcinoma register second line treatment . The combination gemcitabine vinflunine yet evaluate first line treatment patient metastatic urothelial carcinoma . Objectives - To compare progression free survival ( FPS ) vinflunine/gemcitabine versus carboplatin/gemcitabine patient locally advance metastatic transitional cell carcinoma urothelial tract unfit cisplatin base chemotherapy due impair renal function . - To evaluate tumour response ( ORR ) , overall survival ( OS ) disease control rate ( DCR ) vinflunine/gemcitabine versus carboplatin/gemcitabine - To assess safety toxicity vinflunine/gemcitabine versus carboplatin/gemcitabine . - To investigate compare Quality life treatment vinflunine/gemcitabine carboplatin/gemcitabine respectively .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion Criteria Signed inform consent . Histological cytological confirm transitional cell carcinoma urothelial tract ( mixed histology include transitional cell carcinoma allow ) . Noncurable unresectable ( T4b ) , locally advanced ( lymph node positive ( N+ ) ) metastatic ( M1 ) urothelial carcinoma ( include renal pelvic tumour , ureteral tumour , urinary bladder tumour urethral primary tumour ) . No prior antineoplastic chemotherapy anticancer drug . Patients receive neoadjuvant adjuvant platinum contain chemotherapy diagnose loco regional recurrent metastatic disease 6 month eligible . Creatinine clearance 30 60 ml/min ( measure Iohexol CrEDTA technique ) ECOG/WHO Performance Status ( PS ) 01 . •≥ 4 week since prior major surgery , ≥ 2 week since prior minor surgery ( i.e . TURB ) ≥ 1 week since prior radiation therapy . Measurable and/or nonmeasurable disease use RECIST v 1:1 criterion define : Measurable disease : lesion measure least one dimension previously irradiate . Longest diameter ≥10 mm lymph node ≥15 mm short axis CT scan MRI . Nonmeasurable disease : lesion previously irradiate , long diameter &lt; 10 mm lymph node 1014 mm short axis CT scan MRI , truly non measurable lesion include bone lesion , ascites , pleural/pericardial effusion , lymphangitis cutis/pulmonitis . CNS metastases and/or leptomeningeal metastasis allow provide adequately treated radiotherapy , stable generate related neurological symptom . Spinal cord compression due metastatic lesion allow provided adequate surgery and/or radiotherapy deliver , metastases stable generate related neurological symptom . No know suspect allergy investigational agent agent give association trial . 18 year age old . Fertile men woman childbearing potential must use secure contraception ( woman intrauterine device , hormonal contraceptive ( contraceptive pill , implant , transdermal patch , hormonal vaginal device injection prolong release ) , men condom female partner describe ) 2 month enter study 6 month end chemotherapy . Exclusion Criteria Not fulfil inclusion criterion describe Pure nontransitional cell carcinoma urothelial . Pronounced hematuria need repeat blood transfusion , palliative radiotherapy bladder palliative resection ( TURB ) . Impaired bone marrow function define WBC &lt; 3.0 x 109/L , neutrophil &lt; 1.5 x 109/L , platelet &lt; 125 x 109/L , haemoglobin &lt; 100 g/L . Impaired liver function define serum bilirubin &gt; 1.5 x upper limit normal ( ULN ) and/or ASAT/ALAT &gt; 2.5 x ULN ( &gt; 5 x ULN know liver metastasis ) . Electrocardiogram ( ECG ) significant modification suggest high risk occurrence angina pectoris high risk arrhythmia . Other malignancy , except adequately treat basal carcinoma squamous cell carcinoma skin insitu cervix carcinoma incidental prostate cancer ( T1a , Gleason score ≤ 6 , PSA &lt; 0.5 ng/ml ) , tumour disease free survival ≥ 5 year . History serious concurrent illness uncontrolled medical disorder ; medical condition might aggravate chemotherapy treatment could control ; include , restrict : Active infection require antibiotic within 2 week study inclusion , Unstable diabetes mellitus , Hypercalcaemia &gt; 2.9 mmol/L ( grade ≥ 2 accord CTCAE v 4.0 ) , Concurrent congestive heart failure NYHA ( class IIIIV ) , Unstable angina pectoris , myocardial infarction within 6 month and/or poorly control hypertension , QTc &gt; 450 m baseline , Inflammatory bowel disease , Peripheral neuropathy grade ≥ 2 accord CTCAE v 4.0 , Patients require treatment ketoconazole , fluconazole , itraconazole , ritonavir , amprenavir , indinavir , rifampicin ( potent CYP3A4 inhibitor inducer ) phenytoin . Pregnant lactating woman . Any psychological , familial , sociological , geographical condition permit protocol compliance medical followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>